Role of Pharmacogenetic Testing in the Risk and Safety Assessment of Valproates: The Ethnic Aspect (Review)
INTRODUCTION. Pharmacogenetic (PGx) testing plays a significant role in predicting the risk of adverse drug reactions (ADRs) associated with valproic acid (VPA) products, which are among the most prescribed medicinal products in neurology and psychiatry. However, the sensitivity and specificity of P...
Saved in:
Main Authors: | N. A. Shnayder (Author), V. V. Grechkina (Author), V. V. Arkhipov (Author), R. F. Nasyrova (Author) |
---|---|
Format: | Book |
Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenetics-Informed Pharmacometabolomics as an Innovative Approach to Assessing the Safety and Risk of Pharmacotherapy with Valproic Acid
by: N. A. Shnayder, et al.
Published: (2023) -
Pharmacokinetics and Pharmacogenetics of Dabigatran
by: A. V. Savinova, et al.
Published: (2021) -
Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020) -
Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters
by: Teresa Iannaccone, et al.
Published: (2021) -
Antipsychotic-Induced Parkinsonism: A Risk Assessment Scale and Personalised Diagnosis Algorithm
by: N. A. Shnayder, et al.
Published: (2022)